Fig. 6: Synthetic transformations of reductive hydroalkylation products.

a Comparison of enecarbamate reductive hydroalkylation with conventional methods for the synthesis of the key intermediate of an immunosuppressant agent. b Synthesis of alkaloids with enecarbamate reductive hydroalkylation as a key step. c Modular synthesis of isotope- or fluorine-labelled central nervous system drugs via enecarbamate reductive hydroalkylation. d Formal synthesis of drug analogues that contain a chiral carbon adjusted to a tertiary amide. All yields refer to isolated yield of purified product. For more details for reaction conditions, see Supplementary Note 1. THF = tetrahydrofuran, DMF = N,N-dimethylformamide, Fmoc = 9-fluorenylmethoxycarbonyl, Fmoc-Lys(Boc)-OH = (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-6-((tert-butoxycarbonyl)amino)hexanoic acid, HATU = 2-(7-azabenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate, HOAT = 1-hydroxy-7-azabenzotriazole, DIEA = N,N-diisopropylethylamine.